Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expert consensus on perioperative treatment for non-small cell lung cancer.
Duan J, Tan F, Bi N, Chen C, Chen KN, Cheng Y, Chu Q, Ge D, Hu J, Huang Y, Jiang T, Long H, Lu Y, Shi M, Wang J, Wang Q, Yang F, Yang N, Yao Y, Ying J, Zhou C, Zhou Q, Zhou Q, Bongiolatti S, Brunelli A, Fiorelli A, Gobbini E, Gridelli C, John T, Kim JJ, Lin SH, Metro G, Minervini F, Novoa NM, Owen DH, Rodriguez M, Sakanoue I, Scarci M, Suda K, Tabbò F, Tam TCC, Tsuchida M, Uchino J, Voltolini L, Wang J, Gao S. Duan J, et al. Among authors: gridelli c. Transl Lung Cancer Res. 2022 Jul;11(7):1247-1267. doi: 10.21037/tlcr-22-527. Transl Lung Cancer Res. 2022. PMID: 35958323 Free PMC article. Review. No abstract available.
New targeted therapies and small-cell lung cancer.
Rossi A, Maione P, Palazzolo G, Sacco PC, Ferrara ML, Falanga M, Gridelli C. Rossi A, et al. Among authors: gridelli c. Clin Lung Cancer. 2008 Sep;9(5):271-9. doi: 10.3816/CLC.2008.n.042. Clin Lung Cancer. 2008. PMID: 18824449 Review.
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer.
Gridelli C, Rossi A, Venturino P, de Marinis F. Gridelli C, et al. Clin Lung Cancer. 2011 Jan;12(1):70-3. doi: 10.3816/CLC.2011.n.010. Clin Lung Cancer. 2011. PMID: 21273183 Clinical Trial.
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C. Gridelli C, et al. Clin Lung Cancer. 2011 Nov;12(6):407-11. doi: 10.1016/j.cllc.2011.05.002. Epub 2011 Jun 25. Clin Lung Cancer. 2011. PMID: 21705281 Free article. Clinical Trial.
Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.
Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, Cappuzzo F, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R. Gridelli C, et al. Lung Cancer. 2012 Jun;76(3):269-79. doi: 10.1016/j.lungcan.2011.12.011. Epub 2012 Jan 21. Lung Cancer. 2012. PMID: 22266040 Review.
The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C, Besse B, Brahmer JR, Crinò L, Felip E, de Marinis F. Gridelli C, et al. Clin Lung Cancer. 2016 May;17(3):161-8. doi: 10.1016/j.cllc.2016.01.004. Epub 2016 Jan 28. Clin Lung Cancer. 2016. PMID: 26908078 Review.
482 results